FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306967089> ?p ?o ?g. }

• W4306967089 endingPage "502" @default.
• W4306967089 startingPage "479" @default.
• W4306967089 abstract "ObjectiveTo enhance the quality of care and clinical outcomes for children and adolescents with major depressive disorder (MDD) and persistent depressive disorder (PDD). The aims are as follows: (1) to summarize empirically based guidance about the psychosocial and psychopharmacologic treatment of MDD and PDD in children and adolescents; and (2) to summarize expert-based guidance about the assessment of these disorders as an integral part of treatment, and the implementation of empirically based treatments for these disorders in clinical practice.MethodStatements about the treatment of MDD and PDD are based upon empirical evidence derived from a critical systematic review of the scientific literature conducted by the Research Triangle Institute International–University of North Carolina at Chapel Hill (RTI-UNC) Evidence-based Practice Center under contract with the Agency for Healthcare Research and Quality (AHRQ). Evidence from meta-analyses published since the AHRQ/RTI-UNC review is also presented to support or refute the AHRQ findings. Guidance about the assessment and clinical implementation of treatments for MDD and PDD is informed by expert opinion and consensus as presented in previously published clinical practice guidelines, chapters in leading textbooks of child and adolescent psychiatry, the DSM-5-TR, and government-affiliated prescription drug information websites.ResultsPsychotherapy (specifically, cognitive−behavioral and interpersonal therapies) and selective serotonin reuptake inhibitor (SSRI) medication have some rigorous (randomized controlled trials, meta-analyses) empirical support as treatment options. Because effective treatment outcomes are predicated in part upon accuracy of the diagnosis, depth of the clinical formulation, and breadth of the treatment plan, comprehensive, evidence-based assessment may enhance evidence-based treatment outcomes.ConclusionDisproportionate to the magnitude of the problem, there are significant limitations in the quality and quantity of rigorous empirical support for the etiology, assessment, and treatment of depression in children and adolescents. In the context of a protracted severe shortage of child and adolescent−trained behavioral health specialists, the demonstration of convenient, efficient, cost-effective, and user-friendly delivery mechanisms for safe and effective treatment of MDD and PDD is a key research need. Other research priorities include the sequencing and comparative effectiveness of depression treatments, delineation of treatment mediators and moderators, effective approaches to treatment nonresponders and disorder relapse/recurrence, long-term effects and degree of suicide risk with SSRI use, and the discovery of novel pharmacologic or interventional treatments. To enhance the quality of care and clinical outcomes for children and adolescents with major depressive disorder (MDD) and persistent depressive disorder (PDD). The aims are as follows: (1) to summarize empirically based guidance about the psychosocial and psychopharmacologic treatment of MDD and PDD in children and adolescents; and (2) to summarize expert-based guidance about the assessment of these disorders as an integral part of treatment, and the implementation of empirically based treatments for these disorders in clinical practice. Statements about the treatment of MDD and PDD are based upon empirical evidence derived from a critical systematic review of the scientific literature conducted by the Research Triangle Institute International–University of North Carolina at Chapel Hill (RTI-UNC) Evidence-based Practice Center under contract with the Agency for Healthcare Research and Quality (AHRQ). Evidence from meta-analyses published since the AHRQ/RTI-UNC review is also presented to support or refute the AHRQ findings. Guidance about the assessment and clinical implementation of treatments for MDD and PDD is informed by expert opinion and consensus as presented in previously published clinical practice guidelines, chapters in leading textbooks of child and adolescent psychiatry, the DSM-5-TR, and government-affiliated prescription drug information websites. Psychotherapy (specifically, cognitive−behavioral and interpersonal therapies) and selective serotonin reuptake inhibitor (SSRI) medication have some rigorous (randomized controlled trials, meta-analyses) empirical support as treatment options. Because effective treatment outcomes are predicated in part upon accuracy of the diagnosis, depth of the clinical formulation, and breadth of the treatment plan, comprehensive, evidence-based assessment may enhance evidence-based treatment outcomes. Disproportionate to the magnitude of the problem, there are significant limitations in the quality and quantity of rigorous empirical support for the etiology, assessment, and treatment of depression in children and adolescents. In the context of a protracted severe shortage of child and adolescent−trained behavioral health specialists, the demonstration of convenient, efficient, cost-effective, and user-friendly delivery mechanisms for safe and effective treatment of MDD and PDD is a key research need. Other research priorities include the sequencing and comparative effectiveness of depression treatments, delineation of treatment mediators and moderators, effective approaches to treatment nonresponders and disorder relapse/recurrence, long-term effects and degree of suicide risk with SSRI use, and the discovery of novel pharmacologic or interventional treatments." @default.
• W4306967089 created "2022-10-21" @default.
• W4306967089 creator A5004586944 @default.
• W4306967089 creator A5023119133 @default.
• W4306967089 creator A5032518803 @default.
• W4306967089 creator A5035514789 @default.
• W4306967089 creator A5041667856 @default.
• W4306967089 creator A5049848402 @default.
• W4306967089 creator A5073574237 @default.
• W4306967089 date "2023-05-01" @default.
• W4306967089 modified "2023-10-11" @default.
• W4306967089 title "Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders" @default.
• W4306967089 cites W1525638174 @default.
• W4306967089 cites W1592263199 @default.
• W4306967089 cites W1633844846 @default.
• W4306967089 cites W168467554 @default.
• W4306967089 cites W1919000277 @default.
• W4306967089 cites W1969570897 @default.
• W4306967089 cites W1974610592 @default.
• W4306967089 cites W1977866915 @default.
• W4306967089 cites W1982888631 @default.
• W4306967089 cites W1990201815 @default.
• W4306967089 cites W1991056345 @default.
• W4306967089 cites W1992323290 @default.
• W4306967089 cites W1992568187 @default.
• W4306967089 cites W1993925129 @default.
• W4306967089 cites W2000931689 @default.
• W4306967089 cites W2002852004 @default.
• W4306967089 cites W2003027810 @default.
• W4306967089 cites W2010329304 @default.
• W4306967089 cites W2022191212 @default.
• W4306967089 cites W2026277667 @default.
• W4306967089 cites W2026644386 @default.
• W4306967089 cites W2029556601 @default.
• W4306967089 cites W2031144911 @default.
• W4306967089 cites W2031775832 @default.
• W4306967089 cites W2033683752 @default.
• W4306967089 cites W2037713369 @default.
• W4306967089 cites W2048973211 @default.
• W4306967089 cites W2050645823 @default.
• W4306967089 cites W2054014670 @default.
• W4306967089 cites W2057515552 @default.
• W4306967089 cites W2059117796 @default.
• W4306967089 cites W2059586337 @default.
• W4306967089 cites W2059654210 @default.
• W4306967089 cites W2060392554 @default.
• W4306967089 cites W2061211489 @default.
• W4306967089 cites W2064556055 @default.
• W4306967089 cites W2073297202 @default.
• W4306967089 cites W2074330391 @default.
• W4306967089 cites W2082411058 @default.
• W4306967089 cites W2083078293 @default.
• W4306967089 cites W2084730590 @default.
• W4306967089 cites W2088892370 @default.
• W4306967089 cites W2093514511 @default.
• W4306967089 cites W2099328792 @default.
• W4306967089 cites W2105938068 @default.
• W4306967089 cites W2108601695 @default.
• W4306967089 cites W2113281483 @default.
• W4306967089 cites W2117055846 @default.
• W4306967089 cites W2118838026 @default.
• W4306967089 cites W2120787826 @default.
• W4306967089 cites W2123436465 @default.
• W4306967089 cites W2129239384 @default.
• W4306967089 cites W2129490713 @default.
• W4306967089 cites W2131945564 @default.
• W4306967089 cites W2140498388 @default.
• W4306967089 cites W2141235716 @default.
• W4306967089 cites W2147289447 @default.
• W4306967089 cites W2147787300 @default.
• W4306967089 cites W2149402043 @default.
• W4306967089 cites W2150123367 @default.
• W4306967089 cites W2153157719 @default.
• W4306967089 cites W2154311416 @default.
• W4306967089 cites W2158282570 @default.
• W4306967089 cites W2158366999 @default.
• W4306967089 cites W2165173845 @default.
• W4306967089 cites W2165665875 @default.
• W4306967089 cites W2166322905 @default.
• W4306967089 cites W2170219130 @default.
• W4306967089 cites W2183950985 @default.
• W4306967089 cites W2188495513 @default.
• W4306967089 cites W2254051562 @default.
• W4306967089 cites W2292271331 @default.
• W4306967089 cites W2320774618 @default.
• W4306967089 cites W2346590466 @default.
• W4306967089 cites W2464353467 @default.
• W4306967089 cites W2471673808 @default.
• W4306967089 cites W2508555717 @default.
• W4306967089 cites W2554464434 @default.
• W4306967089 cites W2558778675 @default.
• W4306967089 cites W2581084710 @default.
• W4306967089 cites W2595388452 @default.
• W4306967089 cites W2595855713 @default.
• W4306967089 cites W2604131039 @default.
• W4306967089 cites W2604739078 @default.
• W4306967089 cites W2606315822 @default.
• W4306967089 cites W2618040738 @default.

• next